Results 11 - 20 of 92 : Previous 1 2 3 4 5 6 7 8 9 Next
Teva and FDA's Never-Ending Court Battle
Teva looses latest battle against the FDA.
Some taxpayers enjoy a 0% rate on capital gains.
The drugmaker charts a different course for its future.
The generic-drug company decides to keep its specialty pharmaceutical subsidiary.
What's better than a high-quality stock? A high-quality stock with the wind at its back.
Tapping the Brakes on the Teva-Barr Deal
The FTC wants more information before it offers its approval.
Barr and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
Sales of generic contraceptives form a powerful lineup of heavy hitters.
The World's Greatest Get-Rich Formula
It's for real.
Teva Has Revenue in All the Wrong Places
Sometimes double-digit growth isn't all it's cracked up to be.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK